Randomized trials should evaluate whether tailored immunomodulatory strategies, including early anti-TNF or anti-IL-6 therapies in IBD and RA, can reduce cardiogenic complications and improve functional recovery, building on pilot data in animal models. This evidence concerns the gene IL6 and inflammatory bowel disease.